Evaluation of the motivation and key drivers of general practitioners in Belgium and Luxembourg to SIMPLIFY or intensify antihypertensive treatment in uncontrolled hypertensive patients

Cross-sectional survey evaluating the motivation and key drivers of general practitioners to SIMPLIFY or intensify antihypertensive treatment in the general uncontrolled hypertensive population treated with at least one antihypertensive agent in Belgium and Luxembourg

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

ISRCTN

Registry ID

ISRCTN16199080

Enrollment

5175

Registered

2017-04-05

Start date

2017-03-16

Completion date

Unknown

Last updated

2022-09-05

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Hypertension Circulatory System Hypertension

Interventions

All participants attend an appointment to see their general practitioner, who is asked to record the following information: 1. Age, sex, weight and height of the patient

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1. Uncontrolled hypertensive patients 2. Treated with at least one antihypertensive drug 3. Consulting a general practitioner 4. Aged 18 years and over

Exclusion criteria

Exclusion criteria: Secondary hypertension.

Design outcomes

Primary

Measure	Time frame
Change in antihypertensive treatment (yes or no) in relation to blood pressure values (controlled or uncontrolled blood pressure) is assessed using information collected at the GP appointment.	—

Secondary

Measure	Time frame
1. Change in antihypertensive treatment (yes or no) in relation to therapeutic compliance is assessed using information collected at the GP appointment 2. Change in antihypertensive treatment (yes or no) in relation to total pill burden is assessed using information collected at the GP appointment 3. Change in antihypertensive treatment (yes or no) in relation to antihypertensive pill burden is assessed using information collected at the GP appointment 4. Change in antihypertensive treatment (yes or no) in relation to type of antihypertensive treatment is assessed using information collected at the GP appointment 5. Change in antihypertensive treatment (yes or no) in relation to comorbidities/CV risk is assessed using information collected at the GP appointment 6. Change in antihypertensive treatment (yes or no) in relation to patient demographics is assessed using information collected at the GP appointment	—

Measure

Time frame

1. Change in antihypertensive treatment (yes or no) in relation to therapeutic compliance is assessed using information collected at the GP appointment 2. Change in antihypertensive treatment (yes or no) in relation to total pill burden is assessed using information collected at the GP appointment 3. Change in antihypertensive treatment (yes or no) in relation to antihypertensive pill burden is assessed using information collected at the GP appointment 4. Change in antihypertensive treatment (yes or no) in relation to type of antihypertensive treatment is assessed using information collected at the GP appointment 5. Change in antihypertensive treatment (yes or no) in relation to comorbidities/CV risk is assessed using information collected at the GP appointment 6. Change in antihypertensive treatment (yes or no) in relation to patient demographics is assessed using information collected at the GP appointment

—

Countries

Belgium, Luxembourg

Outcome results

None listed

Source: ISRCTN (via WHO ICTRP) · Data processed: Feb 15, 2026